青瓜视频

A world-first genetic test, partly developed by University of Manchester scientists  that could save the hearing of hundreds of babies each year, has been developed and successfully piloted in the NHS.

Taking just 25 minutes, the bedside machine identifies whether a critically ill baby admitted to intensive care has a gene that could result in permanent hearing loss if they are treated with a common emergency antibiotic.

The new swab test technique would replace a test that traditionally took several days and could save the hearing of 180 babies in England alone every year.

People admitted to intensive care are usually given an antibiotic called Gentamicin within 60 minutes. While Gentamicin is used to safely treat about 100,000 babies a year, one in 500 babies carry the gene that can make it cause permanent hearing loss.

Developed in Manchester, the new test means that babies found to have the genetic variant can be given an alternative antibiotic within the 青瓜视频榞olden hour.青瓜视频�

It is expected the test could save the NHS 青瓜视频5 million every year by reducing the need for other interventions, such as cochlear implants.

First-year nursing student Mary, from Preston, is mother to 18-month-old Khobi, who was born and treated at Saint Mary青瓜视频檚 Hospital, part of Manchester University NHS Foundation Trust.

Mary said: 青瓜视频淜hobi was born with her bowel outside her tummy, which put her at risk of infection - she needed antibiotics quickly but was given this new genetic test which showed she was susceptible to hearing loss from gentamicin.

青瓜视频淪he was given an alternative antibiotic which didn青瓜视频檛 affect her hearing, and it worked well. She青瓜视频檚 doing fine and is such a happy, sociable baby.

青瓜视频淭his test is great, and I think all babies should have it.青瓜视频�

NHS national medical director Stephen Powis said: 青瓜视频淭he successful trial of this bedside test is fantastic news for the hundreds of babies - and their parents - who would otherwise lose their hearing when given this common antibiotic in intensive care situations.

青瓜视频淭hrough world-class innovation, the NHS is delivering cutting edge treatments to save and improve patients青瓜视频� lives as well as delivering on the commitments of the NHS Long Term Plan.青瓜视频�

Professor Bill Newman, a consultant in genomic medicine at Manchester University NHS Foundation Trust and Professor of Translational Genomic Medicine at the University of Manchester, led the Pharmacogenetics to Avoid Loss of Hearing (PALoH) study. He said: 青瓜视频淚 am absolutely thrilled with the success of the study, and that this testing is now going to be used in three of our Trust青瓜视频檚 Neonatal Intensive Care Units -  it青瓜视频檚 actually going to make a real difference so babies are not going to lose their hearing for a preventable reason.

青瓜视频淭he trial demonstrated that you can deploy rapid genetic testing in a clinical setting, and that the tests can be carried out within the 青瓜视频榞olden hour青瓜视频� when severely unwell babies should be treated with antibiotics.青瓜视频�

Following the completion of the ground-breaking study, the NHS Genomic Medicine Service Alliance and the NHS will be exploring how this technology can be launched as part of a clinical service through the NHS Genomic Medicine Service.

Around 300 nurses are being trained to use the machine across MFT at Saint Mary青瓜视频檚 Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals青瓜视频� neonatal units within weeks, which are part of Saint Mary青瓜视频檚 Managed Clinical Service within the Trust.

Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS, said: 青瓜视频淕enomic medicine is transforming healthcare, and this is a powerful example of how genetic testing can now be done extremely quickly and become a vital part of triage - not only in intensive care but across our services.

青瓜视频淚t also shows the importance of thinking about how advances in technology can rapidly transform how we use genomics closer to care for our patients.青瓜视频�

Professor Newman, who is Associate Lead, Hearing Health Genomic Solutions at NIHR Manchester Biomedical Research Centre (BRC), said the team had successfully transferred the accuracy of the machine in the lab to working effectively in a ward. At the same time, clinicians adapted quickly to incorporate the test into their routine care for very sick children in the neonatal ward.

The idea for the test came five years ago, and trials started in 2020 with further adaptations and fine-tuning so that the current machine, which is called the Genedrive System, is now fully CE certified to be used in a clinical setting.

Study 青瓜视频� the top-ranked paediatrics journal in the world 青瓜视频� last week.

Backed by 青瓜视频900,000 funding from the National Institute for Health Research (NIHR) and support from the charity Royal National Institute for Deaf People, the Genedrive System, which costs 青瓜视频80 per baby, was developed by Genedrive, a start-up based at the University of Manchester. It was developed in close collaboration with Professor Newman青瓜视频檚 team at Manchester Biomedical Research Centre.

Mike Hobday, Director of Policy and Campaigns at the National Deaf Children青瓜视频檚 Society, said: 青瓜视频淭he National Deaf Children青瓜视频檚 Society welcomes the publication of this important study. The introduction of a rapid test to identify susceptibility to deafness caused by the antibiotic gentamicin will be greatly valued by many families of newborn babies.

青瓜视频淯p to now the genetic test has taken too long to return from the lab to be useful for babies requiring urgent treatment but a rapid test will be a game-changer.青瓜视频�

David Budd, CEO of Genedrive, said: 青瓜视频淭here is a significant drive within the NHS to alert healthcare professionals to the impact of antibiotic-induced hearing loss and encourage them to consider genetic testing prior to initiation of treatment. 

青瓜视频淚t青瓜视频檚 a great example of using human genetics to guide specific therapy, which is now taking front and centre in clinical management globally. The application of Genedrive青瓜视频檚 technology shows how a rapid, affordable, point-of-care test could impact patients青瓜视频� treatment and quality of life across this as well as a wide range of fields.青瓜视频�